Perspective Therapeutics (CATX): Director Granted 75,000 Options at $3.38

Maria E. Martinez, a director of Perspective Therapeutics, Inc. (CATX), was granted 75,000 stock options on 09/03/2025 with an exercise price of $3.38.

Rhea-AI Filing Summary

Maria E. Martinez, a director of Perspective Therapeutics, Inc. (CATX), was granted 75,000 stock options on 09/03/2025 with an exercise price of $3.38. The options vest monthly over three years in 36 substantially equal installments beginning one month after the grant date, are exercisable beginning 09/03/2025, and expire on 09/03/2035. After the reported transaction the reporting person beneficially owns 75,000 shares underlying the option on a direct basis. The Form 4 was signed on behalf of Maria E. Martinez by an attorney-in-fact on 09/05/2025.

Positive

• 75,000 stock options granted to Reporting Person, explicitly disclosed
• Exercise price of $3.38 and 10-year expiration (09/03/2035) clearly stated
• Vesting over 36 monthly installments beginning one month after the grant date is documented

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received 75,000 stock options at $3.38 with standard multi-year monthly vesting; routine executive compensation event.

The grant of 75,000 options at a $3.38 exercise price, vesting over three years in 36 monthly installments, represents a typical equity incentive intended to retain and motivate a board member or executive through continued service. The ten-year term to 09/03/2035 is standard for equity awards. The transaction does not disclose cash proceeds received beyond the exercise price and reports the options as directly beneficially owned following the grant.

Corporate Governance Expert

TL;DR: Governance event is routine and transparent; vesting schedule ties compensation to service tenure.

The Form 4 documents a transparent options grant to a director with clearly stated vesting terms (36 monthly installments starting one month after grant) and a ten-year expiration. From a governance perspective, monthly vesting over three years aligns the directors economic interest with ongoing service without immediate full dilution. The filing was executed by an attorney-in-fact and properly reported on Form 4, meeting disclosure requirements.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Martinez Maria E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	75,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. Options vest and become exercisable over three years in 36 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What security was reported on the Form 4 for Perspective Therapeutics (CATX)?

The Form 4 reports a grant of stock options (right to buy Common Stock) for the reporting person.

How many options were granted to Maria E. Martinez and at what price?

75,000 options were granted with an exercise price of $3.38.

When do the options vest and when do they expire?

Options vest in 36 substantially equal monthly installments beginning one month after the grant date (grant date 09/03/2025) and expire on 09/03/2035.

How many shares does the reporting person beneficially own after the transaction?

Following the reported transaction the reporting person beneficially owns 75,000 shares underlying the option on a direct basis.

Who filed the Form 4 and when was it signed?

The Form 4 was filed for Maria E. Martinez and signed by an attorney-in-fact (Chris Nenno) on 09/05/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/05/2025 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martinez Maria E

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$3.38	09/03/2025		A		75,000		(1)	09/03/2035	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. Options vest and become exercisable over three years in 36 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Maria E Martinez by Chris Nenno, as Attorney-in-Fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.